FindTrial
Sign In

studies on the role of HDAC inhibitors to reverse cisplatin resistance in animal models with ovarian cancer developed using tumor tissue from patients

Studies on the role of HDAC inhibitors in reprogramming cancer cell metabolism to reverse cisplatin resistance in patient derived xenograft model of ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/04/033090
Enrollment
37
Registered
2021-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C569- Malignant neoplasm of unspecifiedovary

Interventions

None listed

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who are diagnosed with ovarian cancer posted for debulking surgery Patients who are diagnosed with ovarian cancer posted for ascetic fluid aspiration Patients with age group > 18 years

Exclusion criteria

Exclusion criteria: Patients who have received chemotherapy before surgery Patients who have received chemotherapy before ascetic fluid aspiration

Design outcomes

Primary

MeasureTime frame
Global histone acetylation/ DNA methylation status, oncogene expression, tumor suppressor gene expression, HDAC and DNMT profile in High grade serous carcinoma of ovary and in the cisplatin resistant ovarian primary cells derived from patients upon HDAC/and DNMT inhibitionTimepoint: Baseline and end of the study.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactVasudha Devi

Melaka Manipal medical College

vasudha.devi@manipal.edu8971494100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026